Correspondence | Published:

DAAs and long-term clinical outcome in hepatitis C: the panacea for all diseases still does not exist

The American Journal of Gastroenterologyvolume 113pages12511266 (2018) | Download Citation


Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    Kwo PY, Shiffman ML, Bernstein DE. The Cochrane review conclusion for hepatitis C DAA therapies is wrong. Am J Gastroenterol. 2018;113:2–4.

  2. 2.

    Jakobsen JC, Nielsen EE, Feinberg J, et al. Direct-acting antivirals for chronic hepatitis C. Cochrane Database Syst Rev. 2017;6:Cd012143.

  3. 3.

    Nappi A, Perrella A, Bellopede P, Lanza A, Izzi A, Spatarella M, Sbreglia C. Safety of new DAAs for chronic HCV infection in a real life experience: role of a surveillance network based on clinician and hospital pharmacist. Infect Agent Cancer. 2017;7:12.

  4. 4.

    Nault JC, Colombo M. Hepatocellular carcinoma and direct acting antiviral treatments: controversy after the revolution. J Hepatol. 2016;65:663–5.

Download references

Author information


  1. VII Department of Infectious Disease and Immunology, Ospedali dei Colli P. O. D. Cotugno, Naples, Italy

    • Alessandro Perrella MD, PhD
  2. Liver Unit, King’s College medical School University, London, UK

    • Alessandro Perrella MD, PhD
  3. Gastroenterology Unit, Università degli Studi della Campania “Luigi Vanvitelli”, Naples, Italy

    • Luca Rinaldi MD
  4. Hepatology Unit, AORN Hospital A. Cardarelli, Naples, Italy

    • Alfonso Galeota-Lanza MD
  5. I Division Infectious Disease, Ospedali dei Colli P. O. D. Cotugno, Naples, Italy

    • Antonio Izzi MD


  1. Search for Alessandro Perrella MD, PhD in:

  2. Search for Luca Rinaldi MD in:

  3. Search for Alfonso Galeota-Lanza MD in:

  4. Search for Antonio Izzi MD in:

Guarantor of the article

Dr Alessandro Perrella accepts full responsibility for the conduct of the study, having access to the data, and being able to control the decision to publish.

Specific author contributions

Dr Alessandro Perrella planned and conducted the study, Dr Luca Rinaldi drafted the manuscript, Dr Alfonso Galeota-Lanza drafted the manuscript, and Dr Antonio Izzi drafted the manuscript.

Financial support


Potential competing interests


Corresponding author

Correspondence to Alessandro Perrella MD, PhD.

About this article

Publication history